![Pipeline Icon](https://jaguar.health/wp-content/uploads/2022/01/Group-421@2x.png)
Learn About Our Key
Near-Term Milestones
Top line results expected forthcoming for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.
![Forest image](https://jaguar.health/wp-content/uploads/2022/01/Mask-Group-140@2x.png)
![Pipeline Icon](http://jaguar.health/wp-content/uploads/2022/01/Group-421@2x.png)
Learn About Our Key Near-Term Milestones
Top line results expected forthcoming for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.